



11 JUN 2007

United States Patent and Trademark Office

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

DAVIS WRIGHT TREMAINE LLP
865 FIGUEROA STREET
SUITE 2400
LOS ANGELES, CA 90017-2566

In re Application of
Yu et al.
Application No.: 10/598,486
PCT No.: PCT/US04/32669
Int. Filing Date: 05 October 2004
Earliest Priority Date: 06 October 2003
Attorney Docket No.: 67789-567
For: Use Of Cox-2 Inhibitor To Prevent T-Cell
Anergy Induced By Dendritic Cell Therapy

DECISION

The petition to revive under 37 CFR 1.137(b) filed 31 August 2006 in the above-captioned application is hereby **GRANTED** as follows:

Applicant states that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional." This statement is being accepted in satisfaction of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has filed the required reply in the form of the basic national fee, and has paid the petition fee. Thus, the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

Review of the declaration of the inventors filed on 31 August 2006 reveals that it is acceptable under 37 CFR 1.497(a) and (b). The \$65.00 small entity surcharge under 37 CFR 1.492(h) (Fee Code 2617) is being charged to Deposit Account No. 04-0258, as authorized by the Transmittal Letter filed on 31 August 2006.

This application is being forwarded to the United States Designated/Elected Office for further processing. Its date under 35 U.S.C. 371(c)(1), (2) and (4) is **31 August 2006**.

George Dombroske
PCT Legal Examiner
Office of PCT Legal Administration
Tel: (571) 272-3283
Fax: (571) 273-0459